What is Decide?
DECIDE operates as a specialized consulting company founded in 2015, focusing on health technology assessment, health economics, and the evaluation of healthcare programs. The firm provides critical support to decision-makers within the healthcare and welfare service sectors, serving a diverse clientele that includes pharmaceutical companies, non-profit organizations, and government agencies. DECIDE's core competencies lie in both qualitative and quantitative assessments, encompassing a range of health economic projects such as cost analyses and real-world evidence studies. Their strategic approach is further enhanced through collaborations with key partners like COWI and the Swedish Institute for Health Economics, positioning them as a vital resource for evidence-based decision-making in healthcare.
How much funding has Decide raised?
Decide has raised a total of $16.5M across 3 funding rounds:
Series A
$2.5M
Series B
$6M
Series C
$8M
Series A (2009): $2.5M with participation from Madrona Venture Group
Series B (2011): $6M led by Madrona Venture Group and Maveron LLC
Series C (2013): $8M supported by Maveron and Madrona Venture Group
Key Investors in Decide
Madrona Venture Group
Madrona Venture Group, established in 1995, is a venture capital firm with a focus on consumer internet, commercial software, and services. They invest in technology companies across various stages of growth.
Maveron LLC
Maveron is a consumer-focused venture capital firm founded in 1998, specializing in early-stage consumer brands that leverage human behavior insights and technological disruption. They are committed to inclusive economic growth and hold B Corp certification.
What's next for Decide?
With a history of substantial enterprise-level capital infusions, including its most recent major strategic investment, Decide is well-positioned for continued expansion and innovation. The company's focus on health technology assessment and health economics, coupled with its established relationships with government agencies and pharmaceutical firms, suggests a trajectory aimed at deepening its impact within the healthcare sector. Future growth is likely to involve leveraging its expertise in real-world evidence and cost-effectiveness analyses to address evolving healthcare challenges and inform policy decisions. The consistent backing from prominent investors indicates strong confidence in Decide's business model and its capacity to deliver value in a complex and critical industry.
See full Decide company page
